ArticleCardiovascular intervention and therapeutics2026
Feasibility and technical considerations of mitral TEER in adults with surgically repaired congenital heart disease: descriptive cohort of OCEAN-mitral registry.
Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in congenital heart surgery have led to a growing population of adults with congenital heart disease (ACHD). Mitral regurgitation (MR) often develops after congenital heart surgery, yet the role and safety of transcatheter edge-to-edge repair (TEER) in this setting remain poorly defined. This descriptive cohort study from the OCEAN-Mitral registry aimed to evaluate the feasibility, procedural characteristics, and short-term outcomes of TEER in adults with surgically repaired congenital heart disease (CHD). Among 3,764 consecutive TEER cases registered between 2018 and 2023, 20 patients (0.5%) had ACHD with prior surgical repair. Baseline characteristics, procedural data, and in-hospital and 30-day outcomes were analyzed using standardized mean differences to account for unequal group sizes. Most ACHD patients (90%) had simple congenital complexity and secondary MR (70%), with preserved left ventricular function and fewer comorbidities than others. All ACHD procedures achieved acute procedural success (100%) with no major intraprocedural complications. Transseptal puncture through surgical atrial septal defect (ASD) patches was feasible and safe under transesophageal echocardiographic guidance. No patients required iatrogenic ASD closure. Hemodynamic parameters improved after TEER, with increased cardiac output and decreased left atrial V-wave pressures. In-hospital mortality and early adverse events were rare. In this descriptive cohort, TEER was technically feasible and safe in adults with surgically repaired CHD, yielding procedural and short-term outcomes comparable to those without repaired ACHD. TEER may represent a viable alternative to repeat surgery in appropriately selected ACHD when performed by experienced multidisciplinary teams.Clinical trials: OCEAN-Mitral registry (UMIN-ID: UMIN000023653).
Indexed as
Identifiers
42020661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.